>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:
  • BGFV +11.8%, X +11.8%, BBOX +11.1%, BGS +10.2%, QLYS +7.8%, KAR+7.8%, (also increases quarterly dividend to $0.35/share, prior $0.32/share), SODA +7.5%, MOD +6.9%, NFX +6.5%, AMRN +5.9%, SCMP+5%, EL +4.7%, GNRC +4.7%, GRMN +4.2%, BBG +3.9%, ICPT +3.8%, SYX+3.2%, MDR +2.4%, APO +2%, WFT +2%, CHRW +1.6%, SB +1.4%, SSW+1.3%, FTR +1.2%, AGN +1.2%, CLX +1.2%, TEX +1%, IOVA +1%, VOYA+0.8%
Select Macau related names showing strength following Macau data:
  • MLCO +4.7%, WYNN +3.1%, LVS +2.5%, MGM +2.4%
Select metals/mining stocks trading higher:
  • AU +2.4%, HMY +2.3%, IAG +1.8%, GG +1.7%, ABX +1%, GDX +1%, GOLD+0.9%, GLD +0.5%, GFI +0.5%
Other news:
  • AVGR +25% (receives 510(k) clearance from the FDA for modifications to the company's Pantheris Lumivascular atherectomy system)
  • ARQL +17.8% (FDA has granted Rare Pediatric Disease Designation to miransertib for the treatment of Proteus syndrome)
  • MBRX +11.9% (announces that responses to the FDA requests for additional information relating to the IND application to study WP1066 as a potential treatment for brain tumors have been submitted)
  • WPRT +9.8% (BRC Gas Equipment was awarded a competitive tender bid by Algeria's National Company for Petroleum Products Marketing and Distribution)
  • WWR +9.5% (reports exploration results in the Columbus Basin)
  • PTI +6.4% (initiates a 'strategic prioritization to focus resources on the research and development of its cystic fibrosis programs ' )
  • TROV +5.6% (withdraws Registration Statement on Form S-3 initially filed with the Commission on September 29, 2017)
  • AKS +4.4% (in sympathy with X earnings)
  • RDHL +2.7% (resubmitted the 505(b)(2) New Drug Application (NDA) for RIZAPORT 10mg to the FDA)
  • WBAI +2.4% (Chairman of the Board and Co-President of Tsinghua Unigroup has stepped down)
  • MDR +2.4% (awarded significant contract from Reliance Industries)
  • PHG +1.6% (pulling back on light volume; District Court enters permanent injunction against Philips North America and two executives to limit distribution of adulterated external defibrillators)
  • NUE +1.3% (in sympathy with X earnings)
  • AGN +1.2% (presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials)
Analyst comments:
  • AAL +2.9% (upgraded to Overweight from Neutral at JP Morgan)
  • MOS +1.1% (upgraded to Sector Perform from Underperform at Scotia)